Before you watch this webinar
Enhancing your learning experience begins with understanding you better. Collecting data enables us to tailor our educational content specifically for our audience. Discover more about how we handle your information in our Privacy Policy.
This area of the website is reserved for healthcare professionals as it contains information created for a healthcare professional audience.
Event
Implementing the 2024 McDonald criteria in the NHS: opportunities and challenges for MS teams
Please note: There is restricted access to the live webinars. Access to the live webinars is for healthcare professionals and a limited number of pharmaceutical representatives. If you are not granted access to the live webinar, you will be able to review the footage, which will be posted on our website shortly after the webinar has been conducted.
Our sponsor
This webinar has received sponsorship from Neuraxpharm. The first session in the webinar is designed and delivered by the MS Academy and sponsored by Neuraxpharm; the sponsor has had no input into the educational content or organisation of the session.
The second session is a promotional satellite symposium that is organised and funded by Neuraxpharm. This satellite symposium is for UK healthcare professionals only.
MS Academy will host a live webinar on Thursday, 15th January at 15:00 GMT. You are invited to watch the webinar from your computer or tablet. We will be live for 1 hour 40 minutes via Zoom and a recording of the MS Academy session will be available following the meeting.
15:00 - 15:50: MS Academy session
15:50 - 15:55: Break
15:55 - 16:40: Neuraxpharm promotional satellite symposium
MS Academy session:
Implementing the 2024 McDonald criteria in the NHS: opportunities and challenges for MS teams
The 2024 McDonald criteria represent a sea-change in MS diagnosis promising earlier and more accurate diagnosis. The new criteria introduce a number of new diagnostic biomarkers that are currently not routinely available in the NHS, but appear to increase the overall rate of MS diagnosis in people with clinically or radiologically isolated syndrome. Are NHS teams ready to implement these changes?
Topics for discussion
- When and how to apply the new criteria?
- How can we get the most out of conventional MRI? Is the NHS ready to implement new MRI techniques like central vein sign
- What is the role of optic nerve evaluation?
- What is the role of CSF evaluation?
- Implications of the new criteria for people newly diagnosed with MS
Dr Wallace Brownlee
Honorary academic director, MS Academy & consultant neurologist and clinical lead, The National Hospital for Neurology and Neurosurgery, London
Dr Andrew Martin
Consultant neuroradiologist, Sheffield Teaching Hospitals NHS Foundation Trust
Dr Sara Collorone
Senior clinical research fellow & consultant neurologist, University College London & Luton and Dunstable University Hospital NHS Foundation Trust
Dr Melanie Hart
Consultant clinical scientist and laboratory director, University College London Hospitals NHS Foundation Trust
Neuraxpharm promotional satellite symposium:
Science matters – discussing the received wisdom of antibody structures and immunogenicity
Objectives
- Provide an overview of anti-CD20 monoclonal antibody therapies in multiple sclerosis (MS)
- Explore structural (scaffold) differences among anti-CD20 monoclonal antibodies
- Discuss the implications of antibody scaffold design on immunogenicity and anti-drug antibodies (ADAs)
- Assess the relationship between immunogenicity, ADAs, and clinical tolerability
Overview
This educational session will examine the scientific principles underpinning antibody structure and immunogenicity in the context of anti-CD20 monoclonal antibodies used in multiple sclerosis. Through a concise overview of available anti-CD20 therapies, including Briumvi® (click here to access prescribing information and adverse event reporting), the presentation will explore how differences in antibody scaffold design may influence immune recognition and the development of anti-drug antibodies. The session will focus on established data and mechanistic understanding, supporting informed clinical discussions around immunogenicity and tolerability. The aim is to enhance scientific understanding of biologic therapy design and its potential clinical implications in MS.
Prof David Baker
Emeritus professor of neuroimmonology, Barts and The London School of Medicine and Dentistry
NXUK/MS/0126/05
This event is free to attend as a result of sponsorship from our sponsors. The current event sponsors are listed on this page. In the interest of Neurology Academy and our sponsors’ legitimate business interests, we make available your name, job title and workplace to our sponsors. It allows us to attract the most appropriate sponsors, delegates and speakers for the events and to facilitate potential collaboration and communication between you and the sponsors; and allows us to offer other relevant events and services to the healthcare and life science industries. You can ask us not to share your your name, job title and workplace by emailing info@neurologyacademy.org. We respect the privacy of every person for whom we have personal data. The group privacy and cookies policy can be viewed here
Book your place now
Our sponsor
This webinar has received sponsorship from Neuraxpharm. The first session in the webinar is designed and delivered by the MS Academy and sponsored by Neuraxpharm; the sponsor has had no input into the educational content or organisation of the session.
The second session is a promotional satellite symposium that is organised and funded by Neuraxpharm. This satellite symposium is for UK healthcare professionals only.
CPD accreditation
We will apply for CPD accreditation from the Royal College of Physicians for this webinar.
Please note CPD Federation approval does not include satellite symposia sessions.
Encouraging excellence, developing leaders, inspiring change
MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.